However, the heterogeneity of BCMA expression on multiple myeloma cells allows anti-BCMA CAR-T cells to preferentially target multiple myeloma cells with high BCMA expression, while to retain multiple myeloma cells with low or no BCMA expression for clonal growth (19–21). This evidence concerns the gene TNFRSF17 and AL amyloidosis.